profit from every $100 of sales.
$0$100
Harmony Biosciences Holdings
$33.76-0.12% today
-1.5% in 1 year
1-year low $26.541-year high $42.86
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $12.49 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Harmony Biosciences Holdings sold, what it kept, and what it did with the cash.
Sales went from $438 million in 2022 to $868 million in 2025, with $159 million of profit last year.
SalesProfit
Harmony Biosciences Holdings vs. similar companies
Harmony Biosciences Holdings grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Harmony Biosciences Holdings | 12.5× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Harmony Biosciences Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 438 | 582 | 715 | 868 | |
| 354 | 461 | 558 | 670 | |
| 120 | 192 | 191 | 208 | |
| 147 | 222 | 233 | 255 | |
| 181 | 129 | 145 | 159 | |
| 2.97 | 2.13 | 2.51 | 2.71 | |
| 80.9% | 79.2% | 78.1% | 77.2% | |
| 27.4% | 33.0% | 26.7% | 24.0% | |
| 41.4% | 22.1% | 20.4% | 18.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 674 | 811 | 999 | 1,272 |
| Cash | 244 | 312 | 453 | 753 |
| Total debt | 192 | 194 | 179 | 164 |
| Total liabilities | 271 | 344 | 340 | 401 |
| 403 | 467 | 659 | 870 | |
| 61 | 60 | 58 | 59 | |
| 16.4% | 23.6% | 19.7% | 17.6% | |
| 45.0% | 27.6% | 22.1% | 18.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 144 | 219 | 220 | 348 | |
| 0 | 0 | 1 | 0 | |
| 144 | 219 | 219 | 348 | |
| Dividends paid | – | – | – | – |
| 0 | 100 | 0 | 0 | |
| 26 | 32 | 43 | 45 |
Valuation
- 12.5×
- 9.6×
- –
- 2.0×
- 2.3×
- 5.7×
- 5.5×
- 17.5%
- 8.0%
- 0.0%
Profitability
- 77.2%
- 24.0%
- 18.3%
- 26.0%
- 12.5%
- 18.1%
- 17.2%
- 11.4%
- 18.0%
- 25.0%
Growth
- +25.6%
- −3.0%
- +59.1%
- –
- −0.0%
Financial health
- -1.6×
- 0.23
- 16.2%
- 13.5×
- 3.58
- 3.56
- 0.71
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 952
Top 15%of 884
Top 16%of 601
Top 21%of 886
Top 3%of 987
What analysts expect
- Average price target
- $46.80
- Range
- $31.00 – $62.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.55 | 0.76 | −27.6% |
| Feb 24, 2026 | 0.38 | 0.84 | −54.8% |
| Nov 4, 2025 | 0.87 | 0.92 | −5.4% |
| Aug 5, 2025 | 0.68 | 0.78 | −12.8% |
| May 6, 2025 | 0.78 | 0.59 | +32.2% |
| Feb 25, 2025 | 0.85 | 0.74 | +14.9% |
| Oct 29, 2024 | 0.79 | 0.67 | +17.9% |
| Aug 6, 2024 | 0.20 | -0.06 | +433.3% |
News
Harmony outlines $1.00B-$1.04B 2026 WAKIX net revenue as CEO transition beginsSeeking Alpha · Nov 4, 2026Why Harmony Biosciences Stock Got Mashed on MondayYahoo Finance · Oct 12, 2026Harmony Gold sees higher full-year earnings as rising metal prices boost revenueSeeking Alpha · Aug 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
81Pass
Benjamin Graham
81Pass
Philip Fisher
75Pass
Peter Lynch
54No pass
Joel Greenblatt
58No pass
Charlie Munger
77Pass
Terry Smith
74Pass
Questions about Harmony Biosciences Holdings
Is Harmony Biosciences Holdings a good stock to buy?
A solid business, and the price looks low. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Harmony Biosciences Holdings AI analysis
What does Harmony Biosciences Holdings do?
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. It is in Biotechnology.
Does Harmony Biosciences Holdings pay a dividend?
No. Harmony Biosciences Holdings does not pay a dividend at the moment.
Is Harmony Biosciences Holdings stock halal?
No. Harmony Biosciences Holdings does not pass our halal screen: its cash and confirmed interest-bearing investments are 38% of its market value, at or above the 33% limit. How we check
How has Harmony Biosciences Holdings stock done over the past year?
Down 1.5% over the past twelve months, to $33.76. It traded between $26.54 and $42.86 and is 21.2% below its high.
Who are Harmony Biosciences Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Harmony Biosciences Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.